Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free EFTR Stock Alerts

eFFECTOR Therapeutics (EFTR) Competitors

eFFECTOR Therapeutics logo
$0.0006 0.00 (0.00%)
As of 05/29/2026 10:33 AM Eastern
Compare

EFTR vs. PXMD, GNCA, SMFL, GNCAQ, and CARM

Should you buy eFFECTOR Therapeutics stock or one of its competitors? MarketBeat compares eFFECTOR Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with eFFECTOR Therapeutics include PaxMedica (PXMD), Genocea Biosciences (GNCA), Smart for Life (SMFL), Genocea Biosciences (GNCAQ), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical products" industry.

How does eFFECTOR Therapeutics compare to PaxMedica?

eFFECTOR Therapeutics (NASDAQ:EFTR) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 4.9% of PaxMedica shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by company insiders. Comparatively, 1.0% of PaxMedica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, PaxMedica had 1 more articles in the media than eFFECTOR Therapeutics. MarketBeat recorded 1 mentions for PaxMedica and 0 mentions for eFFECTOR Therapeutics. eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
PaxMedica Neutral

eFFECTOR Therapeutics has a beta of 2.41, indicating that its share price is 141% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market.

PaxMedica is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

eFFECTOR Therapeutics' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
PaxMedica N/A -3,167.89%-560.35%

Summary

eFFECTOR Therapeutics beats PaxMedica on 6 of the 9 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.41, meaning that its share price is 141% more volatile than the broader market.

Genocea Biosciences has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

eFFECTOR Therapeutics' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
eFFECTOR Therapeutics N/A N/A N/A

In the previous week, Genocea Biosciences had 1 more articles in the media than eFFECTOR Therapeutics. MarketBeat recorded 1 mentions for Genocea Biosciences and 0 mentions for eFFECTOR Therapeutics. Genocea Biosciences' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
eFFECTOR Therapeutics Neutral

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

eFFECTOR Therapeutics beats Genocea Biosciences on 6 of the 10 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Smart for Life?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Smart for Life has higher revenue and earnings than eFFECTOR Therapeutics. Smart for Life is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Smart for Life Neutral

eFFECTOR Therapeutics has a beta of 2.41, suggesting that its stock price is 141% more volatile than the broader market. Comparatively, Smart for Life has a beta of 13.95, suggesting that its stock price is 1,295% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Smart for Life N/A N/A N/A

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Smart for Life shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Comparatively, 31.7% of Smart for Life shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Smart for Life beats eFFECTOR Therapeutics on 4 of the 7 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCAQ) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/AN/AN/AN/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

Genocea Biosciences has a beta of 2.44, suggesting that its stock price is 144% more volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.41, suggesting that its stock price is 141% more volatile than the broader market.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
eFFECTOR Therapeutics Neutral

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

eFFECTOR Therapeutics beats Genocea Biosciences on 3 of the 4 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Carisma Therapeutics?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

Carisma Therapeutics has a consensus target price of $1.00, indicating a potential upside of 999,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than eFFECTOR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
eFFECTOR Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Carisma Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

eFFECTOR Therapeutics has a beta of 2.41, meaning that its share price is 141% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

eFFECTOR Therapeutics has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Carisma Therapeutics -254.28%N/A -192.17%

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Carisma Therapeutics Neutral

eFFECTOR Therapeutics has higher earnings, but lower revenue than Carisma Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00

Summary

Carisma Therapeutics beats eFFECTOR Therapeutics on 8 of the 13 factors compared between the two stocks.

Get eFFECTOR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EFTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

EFTR vs. The Competition

Export
MetriceFFECTOR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3K$973.06M$6.43B$12.59B
Dividend YieldN/A4.84%2.69%5.33%
P/E Ratio0.001.4721.6326.26
Price / SalesN/A119.76565.57116.53
Price / CashN/A20.0643.2256.84
Price / Book0.007.6810.557.30
Net Income-$35.81M-$3.80M$3.56B$337.27M
7 Day PerformanceN/A2.84%2.86%3.58%
1 Month PerformanceN/A73.09%4.59%5.71%
1 Year PerformanceN/A114.90%37.68%39.75%

eFFECTOR Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/A+500.0%$3KN/AN/A10
PXMD
PaxMedica
N/A$0.00
+40.0%		N/AN/A$8KN/AN/A2
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
SMFL
Smart for Life
N/A$0.00
+50.0%		N/A+125.0%$6K$11.11MN/A110
GNCAQ
Genocea Biosciences
N/A$0.00
flat		N/AN/A$5KN/AN/A70

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EFTR) was last updated on 5/31/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel